Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Triple Negative Breast Cancer
NCT05722795Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Jun 2023
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imatinib in triple-negative breast cancer (TNBC), sponsored by Region Västra Götaland. Primary endpoint: Proportion of patients that convert to ER expressing breast cancer. Started Jun 2023; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05722795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722795.